Biotech 2050 открытые
[search 0]
Больше
Download the App!
show episodes
 
Loading …
show series
 
Synopsis: On the Biotech2050 podcast, Tuyen Ong, CEO at Ring Therapeutics and CEO partner at flagship pioneering, shared his journey from a medical background to leading innovative gene therapy companies, highlighting the importance of cross-disciplinary expertise in driving biotech advancements. His insights into the gene therapy landscape and the…
  continue reading
 
Synopsis: In a recent episode of Biotech2050, hosted by Alok Tayi, Kristen Fortney, CEO of BioAge, provides valuable insights into the evolving landscape of aging biology and the innovative approach BioAge is taking to identify therapeutic targets. Kristen's background in aging biology, genetics, and statistics underscores her expertise in the fiel…
  continue reading
 
Synopsis: In this episode of the Biotech2050 podcast, Chris Gibson, the co-founder and CEO of Recursion, shares insights on the intersection of technology and biotech, emphasizing the importance of adaptability and diverse partnerships in driving innovation. Gibson's journey from pursuing an MD-PhD program with a focus on merging engineering and me…
  continue reading
 
Synopsis: Christian Angermayer, a prominent investor and entrepreneur in the biotech industry, shares valuable insights in the Biotech2050 podcast, shedding light on the challenges and opportunities within the sector. Drawing from his extensive experience, Angermayer emphasizes the importance of making biotech more accessible to a broader audience …
  continue reading
 
Synopsis: In this episode of the Biotech2050 podcast, David Kirn, CEO of 4D Molecular Therapeutics, shares invaluable insights for aspiring entrepreneurs in the biotech industry. Kirn discusses the development of his company's platform that integrates gene therapy and directed evolution to create innovative treatments for genetic diseases. By utili…
  continue reading
 
Synopsis:In this episode of the Biotech2050 podcast, David Esposito, CEO of ONL Therapeutics, provides valuable insights into the challenges and opportunities in the field of ophthalmology. Esposito's extensive career journey, from the United States Military Academy to leading ONL Therapeutics, underscores his deep understanding of the industry. He…
  continue reading
 
Synopsis: In this episode of the Biotech2050 podcast, Jak Knowles, co-founder of Affini-T Therapeutics, shares valuable insights into the challenges faced by bootstrapped biotech companies and the significance of venture capital in the industry. Knowles discusses the importance of finding key partners and securing intellectual property early on, sh…
  continue reading
 
Synopsis: Sean Bohen, M.D., Ph.D., is the President and CEO of Olema Oncology, a biopharmaceutical company developing innovative targeted therapies for women’s cancers. We’re excited to welcome Sean back to the podcast – he last appeared on episode 130 in late 2022. Sean provides an update on all the exciting things that have happened at Olema sinc…
  continue reading
 
Synopsis: Troy Wilson, Ph.D., J.D., is the President and CEO of Kura Oncology, a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. Troy talks about his experiences being a CEO and the differences in responsibility between being a CEO and a board member. He also shares wha…
  continue reading
 
Synopsis: Keith Gottesdiener, MD, and Jeremy Duffield, MD, PhD, FRCP, are the President & CEO and CSO, respectively, of Prime Medicine. Prime Medicine was founded to bring the promise of gene editing to patients. They use Prime Editing, a next-generation technology that can “search and replace” to restore normal genetic function almost anywhere in …
  continue reading
 
Synopsis: Brett Hall, Ph.D., is the CSO of Immuneering, a public, clinical-stage oncology company dedicated to developing medicines for broad populations of cancer patients by applying its deep knowledge of translational bioinformatics to every stage of the drug development process. Brett talks about his background in the military targeting nuclear…
  continue reading
 
Synopsis: Ivana Magovčević-Liebisch, PhD, JD, is the President and CEO of Vigil Neuroscience, a microglia-focused company dedicated to improving the lives of patients, caregivers, and families affected by rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel cells of the brain’s immune system. Ivana shares…
  continue reading
 
Synopsis: Bobak Azamian, MD, Ph.D., is the CEO and Chairman of Tarsus Pharmaceuticals, a biopharmaceutical company that applies proven science and new technology to revolutionize treatment for patients, starting with eye care. Bobby talks about his early years working in the venture capital space before founding his first company. He shares what it…
  continue reading
 
Synopsis: Nima Farzan is the CEO of Kinnate Biopharma, a clinical-stage precision oncology company focused on expanding on the promise of targeted therapies for those battling cancer. The company is developing medicines for known oncogenic drivers where there are no approved targeted drugs. Having started his biotech career in the late 90s, Nima di…
  continue reading
 
Synopsis: Mark Litton, Ph.D., is the President and CEO of Athira Pharma, a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration for those suffering from Alzheimer’s, Parkinson’s disease, dementia, and more. Mark talks about being a CEO for the first time and what h…
  continue reading
 
Synopsis: Ram Aiyar, Ph.D., MBA, is the President & CEO of Korro Bio. Korro Bio harnesses the body’s natural RNA editing machinery to make precise, single-base RNA edits to modulate protein function, addressing the medical needs of patients. Having founded several companies, Ram talks about some of the non-obvious differences in terms of being seni…
  continue reading
 
Synopsis: Seemay Chou, Ph.D., is the Co-Founder and CEO of Arcadia Science, a research and development company leveraging the biology of emerging research organisms. Seemay sits down with Alok to discuss her move from academic science into an entrepreneurial role and her advice for others looking to make a similar transition. She talks about Arcadi…
  continue reading
 
Synopsis: Michelle Werner is the CEO of Alltrna and a CEO-Partner at Flagship Pioneering. Alltrna is the world’s first tRNA platform company to decipher tRNA biology and pioneer tRNA therapeutics to treat thousands of diseases. Flagship Pioneering conceives, creates, resources, and develops first-in-category bioplatform companies to transform human…
  continue reading
 
Synopsis: Bernard Coulie is the President and CEO of Pliant Therapeutics, a clinical stage biopharmaceutical company focused on discovering and developing novel therapeutics that seek to halt progression of fibrotic diseases — ultimately preserving organ function. Bernard discusses the arc of his career and shares his perspective on the European bi…
  continue reading
 
Synopsis: Mahesh Karande is the President and CEO of Omega Therapeutics, a clinical-stage biotechnology company pioneering the development of a new class of programmable epigenomic mRNA medicines for unprecedented control of gene regulation and cellular function. Through its OMEGA platform, the company engineers mRNA therapeutics called Omega Epige…
  continue reading
 
Synopsis: Joseph Payne is the Founder, President and CEO of Arcturus Therapeutics, a global late-stage clinical messenger RNA medicines and vaccines company focused on the discovery, development and commercialization of therapeutics for rare diseases and vaccines. Joseph discusses the founding story behind Arcturus and the impetus behind starting h…
  continue reading
 
Synopsis: Robert Blum and Fady Malik are the President & CEO and EVP, Research and Development, respectively, of Cytokinetics, ​​a late-stage biopharmaceutical company committed to developing potential medicines that impact the mechanics of muscle and may improve the lives of people living with debilitating diseases. Robert and Fady discuss how the…
  continue reading
 
Synopsis: James McArthur is the CEO of PepGen, a biotech company creating a pipeline of disease-modifying therapeutics with the potential to safely and effectively target the root cause of serious genetic diseases, with an initial focus on neuromuscular diseases. James talks about his experience on the venture capital side and how that has influenc…
  continue reading
 
Synopsis: Paul Lammers, M.D., is the CEO of Triumvira Immunologics, a clinical-stage immuno-oncology company developing unique, targeted autologous and allogeneic T cell therapeutics that co-opt the natural biology of T cells to treat a broad range of patients with cancer. A Dutch-trained biologist and physician, Paul talks about starting his caree…
  continue reading
 
Synopsis: Andrew Scharenberg is the Co-founder and CEO of Umoja Biopharma, a company pioneering the future of immunotherapy by reprogramming T cells in vivo. Umoja’s groundbreaking integrated platform therapeutics reprogram the immune system in the patient’s body to target cancer cells and generate lasting remissions. Andrew talks about the CAR T-c…
  continue reading
 
Synopsis: Theresa Heah, M.D., is the CEO of Intergalactic Therapeutics. Intergalactic is overcoming the limitations of viral-based gene therapy and developing a best-in-class non-viral alternative. Intergalactic uses synthetic biology and engineered gene circuits to make covalently closed and circular DNA (“C3DNA”) molecules designed to provide a p…
  continue reading
 
Synopsis: Volker Herrmann is the President and CEO of Sonata Therapeutics, a Flagship Pioneering company revolutionizing the world’s understanding of the cellular microenvironment and its importance to human biology and disease. Sonata’s product-platform creates drugs based on a systematic, comprehensive characterization of the microenvironment in …
  continue reading
 
Synopsis: Greg Flesher is the President and CEO of Reneo Pharmaceuticals, a clinical-stage pharmaceutical company focused on the development of therapies for patients with rare genetic mitochondrial diseases with significant unmet medical needs. Greg discusses beginning his career at Eli Lilly in the mid 1990s and how he approaches being a CEO diff…
  continue reading
 
Synopsis: Adrian Gottschalk is the president and CEO of Foghorn Therapeutics, a clinical-stage biotechnology company pioneering a new class of medicines that treat cancers and other serious diseases by correcting abnormal gene expression. Adrian discusses his early beginnings at Biogen before joining Foghorn. He talks about the evolution of his rol…
  continue reading
 
Synopsis: Jim Brown is the President and CEO of DURECT Corporation, a biopharmaceutical company committed to transforming the treatment of acute organ injuries and chronic liver diseases by advancing novel and potentially lifesaving epigenetic therapies. Jim discusses how his early beginnings as a vet ultimately led him to the biotech industry. He …
  continue reading
 
Synopsis: James Peyer, Ph.D., is the Founder and CEO of Cambrian Bio, a clinical-stage drug-development company focused on creating therapies to prevent and cure age-related diseases. James discusses the driving force behind his interest in aging biology and oncology, how his perspective on aging has changed over the years, his entrepreneurial jour…
  continue reading
 
Synopsis: Gary Lee, Ph.D. is the CSO of Lyell Immunopharma, a T-cell reprogramming company dedicated to developing cell therapies for patients with solid tumors. A chemical engineer by training, Gary has been working in the gene therapy field for 20+ years. He discusses how he’s observed the cell therapy space evolve over the last couple of decades…
  continue reading
 
Synopsis: Liang Schweizer, Ph.D. is the Founder and CEO of HiFiBiO Therapeutics, a clinical-stage global biotech company mobilizing the human immune system to combat disease. The company employs its unique Drug Intelligence Science (DIS®) platform, which combines its proprietary microfluidic single-cell platform with advanced AI/ML-based data analy…
  continue reading
 
Synopsis: Detlev Biniszkiewicz is the Founder and CEO of NextPoint Therapeutics, a company advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 pathway. Detlev discusses the immuno-oncology landscape including its challenges and opportunities, and the work his team is pursuing at NextPoint to deliver new the…
  continue reading
 
Synopsis: Eric Dobmeier is the President and CEO of Chinook Therapeutics, a clinical-stage biopharmaceutical company discovering, developing and commercializing precision medicines for rare, severe chronic kidney diseases. Eric discusses how his early years as a lawyer working in-house as general counsel for Seattle Genetics (now Seagen), ultimatel…
  continue reading
 
Synopsis: Faraz Ali is the CEO of Tenaya Therapeutics, a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease. Faraz discusses his non-traditional background as an electrical engineer before he found his passion for applying science an…
  continue reading
 
Synopsis: Gregory Verdine, Ph.D., is the Co-Founder, President and CEO of LifeMine Therapeutics and FogPharma. LifeMine Therapeutics is reinventing drug discovery by mining genetically-encoded small molecules (GEMs) from the biosphere. FogPharma is developing a new class of drugs to address the limitations of today’s precision medicines and achieve…
  continue reading
 
Synopsis: Kate Haviland is the CEO of Blueprint Medicines, a global precision therapy company that creates life-changing medicines for people with cancer and blood disorders. Applying an approach that is both precise and agile, they create medicines that selectively target genetic drivers, with the goal of staying one step ahead across stages of di…
  continue reading
 
Synopsis: Asit Parikh, M.D., Ph.D., is the President and CEO of MOMA Therapeutics, a biotech company discovering the next generation of precision medicines by targeting highly dynamic proteins that underlie human disease. Asit discusses his experience and learnings being the CEO of a biotech for the first time and his approach to recruiting high qu…
  continue reading
 
Synopsis: Samir Ounzain is the CEO and Co-Founder of HAYA Therapeutics, a precision medicines company developing RNA-guided programmable therapeutics targeting the regulatory genome for serious health conditions including fibrosis. Samir discusses the current landscape as it relates to precision medicine and genomic medicine and what his team is ho…
  continue reading
 
Synopsis: Sekar Kathiresan is the Co-Founder, CEO and Board Member of Verve Therapeutics, a clinical-stage biotechnology company developing gene editing medicines to treat patients with cardiovascular disease. Sekar discusses Verve’s work developing single-course, in vivo liver-directed gene editing medicines for patients with and at risk of cardio…
  continue reading
 
Synopsis: Harlan Robins, Ph.D., is the CSO and Co-Founder of Adaptive Biotechnologies, a pioneer and leader in immune-driven medicine that aims to improve people’s lives by learning from the wisdom of their adaptive immune systems. Adaptive’s proprietary immune profiling platform reveals and translates insights from our adaptive immune systems with…
  continue reading
 
Synopsis: Dr. Paul Bolno is the President and CEO of Wave Life Sciences, a clinical-stage RNA medicines company committed to delivering life-changing treatments for people battling devastating diseases including Duchenne muscular dystrophy and Alpha-1 antitrypsin deficiency. Paul discusses his early years at GSK and the events that led him to join …
  continue reading
 
Synopsis: Garo Armen, Ph.D., is the Chairman and CEO of Agenus, an immuno-oncology company with the goal of treating cancers with novel combinations utilizing its unique portfolio of checkpoint antibodies, tumor microenvironment modifiers, vaccines and adjuvants. After receiving his Ph.D. in chemistry, Dr. Armen worked on Wall Street where he speci…
  continue reading
 
Synopsis: Craig Thompson is the CEO of Cerevance, a clinical-stage drug discovery and development company focused on developing novel therapeutics for central nervous system diseases. He discusses the arc of his career, beginning at big pharma at Merck and Pfizer before transitioning to biotech, and his learnings along the way. As CEO, he shares wh…
  continue reading
 
Synopsis: We recorded this episode in December 2022 with Florian Brand and Srinivas Rao, the Co-Founders and CEO & CSO, respectively, of atai Life Sciences, a biopharmaceutical company that leverages a decentralized platform approach to incubate and accelerate the development of highly effective mental health treatments that address the unmet needs…
  continue reading
 
Synopsis: Kevin Judice is the Co-Founder and CEO of DICE Therapeutics, a clinical-stage biopharmaceutical company developing transformative medicines for autoimmune and inflammatory diseases. Kevin trained as an organic chemist in graduate school before beginning his career at Genentech in the early 90s. He talks about stepping into the CEO role fo…
  continue reading
 
Synopsis: Tariq Kassum, M.D. is the CEO of Celsius Therapeutics, a company pioneering new precision medicines in inflammatory disease by harnessing the power of single-cell RNA sequencing and human biology at scale. Tariq shares his unique journey from med school, to working in Wall Street as a biotech investment banker and stock analyst, to the co…
  continue reading
 
Synopsis: Prakash Raman, Ph.D., is the President and CEO of Ribon Therapeutics, a clinical stage biopharmaceutical company pursuing the development of novel small molecules targeting stress support pathways in cancer and inflammation. A medicinal chemist by training, Prakash discusses his professional development and the evolution of his strategic …
  continue reading
 
Synopsis: Joel Schneider, Ph.D. and Robert Kotin, Ph.D. are the President & CEO and Founder & Chief Technology Advisor, respectively, of Carbon Biosciences, an emerging leader in the development of novel parvovirus-derived gene therapies. Joel and Robert sit down with host Rahul Chaturvedi to discuss the arc of their careers, how the AAV field has …
  continue reading
 
Loading …

Краткое руководство